Publication
A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.
Firas Hatoum, Brandon Dyer, Jazlyn Heiligh, Trey Poehlman, Jingsong Zhang, Gigi Jameel, Sarah Mizelle, Aditi Patel, Amy Schneider, Adnan Fazili, Jeffrey S Johnson, Justin W Miller, Gabriel Roman Souza, Nadine Mahmoud, Keerthi Gullapalli, Youngchul Kim, Philippe E Spiess, Robert Gatenby, Alexander R A Anderson, Jad Chahoud
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT06860386registry_reference1.00
Registered trialsNCT06860386
Curated evidence
Evidence citing this paper (0)
Data not yet available